|
|
Volumn 488, Issue 7411, 2012, Pages 267-
|
|
Generic HIV drugs will widen US treatment net
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR;
ANTIRETROVIRUS AGENT;
DARUNAVIR;
DELAVIRDINE;
EFAVIRENZ;
EMTRICITABINE;
GENERIC DRUG;
LAMIVUDINE;
RITONAVIR;
TENOFOVIR;
TIPRANAVIR;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
CLINICAL PROTOCOL;
CLINICAL TRIAL (TOPIC);
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFICACY;
ECONOMIC EVALUATION;
HEALTH CARE COST;
HEALTH CARE ORGANIZATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MEDICINE;
NOTE;
PATENT;
PATIENT CARE;
PILL;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
TREATMENT INDICATION;
UNITED STATES;
ADENINE;
ANTI-HIV AGENTS;
BUDGETS;
CARBAMATES;
COST-BENEFIT ANALYSIS;
DEOXYCYTIDINE;
DRUG COMBINATIONS;
DRUG COSTS;
DRUGS, GENERIC;
FEDERAL GOVERNMENT;
HUMANS;
OXAZINES;
PATENTS AS TOPIC;
PHOSPHONIC ACIDS;
QUINOLONES;
THIAZOLES;
UNITED STATES;
|
|
EID: 84865110151
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/488267a Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
